Cemiplimab/Peg-Interferon-α in Advanced CSCC

NCT05729139 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI is leaving institution prior to study opening for accrual.

Conditions

Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma
Advanced Squamous Cell Carcinoma

Interventions

DRUG: Cemiplimab-Rwlc
DRUG: PEG-IFN alfa-2a

Sponsor

Baptist Health South Florida

Collaborators

[object Object]